Detecting the activity of CRISPR gene editing tools in organisms with the naked eye and an ultraviolet flashlight is now possible using technology developed at ORNL.
Carrie Eckert applies her skills as a synthetic biologist at ORNL to turn microorganisms into tiny factories that produce a variety of valuable fuels, chemicals and materials for the growing bioeconomy.
As a metabolic engineer at Oak Ridge National Laboratory, Adam Guss modifies microbes to perform the diverse processes needed to make sustainable biofuels and bioproducts.
In a step toward increasing the cost-effectiveness of renewable biofuels and bioproducts, scientists at ORNL discovered a microbial enzyme that degrades tough-to-break bonds in lignin, a waste product of biorefineries.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
Deborah Frincke, one of the nation’s preeminent computer scientists and cybersecurity experts, serves as associate laboratory director of ORNL’s National Security Science Directorate. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy
A research team led by Oak Ridge National Laboratory bioengineered a microbe to efficiently turn waste into itaconic acid, an industrial chemical used in plastics and paints.
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.